CVMCEL SCI CORP

NYSE cel-sci.com


$ 1.42 $ -0.04 (-2.74 %)    

Wednesday, 01-May-2024 15:59:51 EDT
QQQ $ 423.50 $ -1.60 (-0.38 %)
DIA $ 380.51 $ -1.01 (-0.26 %)
SPY $ 502.00 $ -2.40 (-0.48 %)
TLT $ 88.22 $ 0.00 (0 %)
GLD $ 212.73 $ 0.27 (0.13 %)
$ 1.42
$ 1.47
$ 0.00 x 0
$ 0.00 x 0
$ 1.42 - $ 1.47
$ 1.04 - $ 3.23
164,454
na
71.15M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-14-2024 12-31-2023 10-Q
2 12-21-2023 09-30-2023 10-K
3 08-10-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 02-14-2023 12-31-2022 10-Q
6 12-27-2022 09-30-2022 10-K
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 02-11-2022 12-31-2021 10-Q
10 12-21-2021 09-30-2021 10-K
11 08-13-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 02-12-2021 12-31-2020 10-Q
14 12-29-2020 09-30-2020 10-K
15 08-10-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-10-2020 12-31-2019 10-Q
18 12-16-2019 09-30-2019 10-K
19 08-14-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 02-14-2019 12-31-2018 10-Q
22 12-19-2018 09-30-2018 10-K
23 08-14-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 02-12-2018 12-31-2017 10-Q
26 12-29-2017 09-30-2017 10-K
27 08-09-2017 06-30-2017 10-Q
28 05-10-2017 03-31-2017 10-Q
29 02-09-2017 12-31-2016 10-Q
30 12-14-2016 09-30-2016 10-K
31 08-09-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 02-09-2016 12-31-2015 10-Q
34 12-11-2015 09-30-2015 10-K
35 08-07-2015 06-30-2015 10-Q
36 05-08-2015 03-31-2015 10-Q
37 02-06-2015 12-31-2014 10-Q
38 12-23-2014 09-30-2014 10-K
39 08-08-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cel-sci-corporation-issues-letter-to-shareholders

CEL-SCI Corporation (NYSE:CVM) today issued a letter to its shareholders. This letter will be sent to the Company's shareho...

 cel-sci-q1-eps-014-up-from-018-yoy

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.14) per share. This is a 22.22 percent increase over losses of $(0.18) per ...

 why-cel-sci-corporation-cvm-shares-are-diving

CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.

 why-u-power-shares-are-trading-lower-by-around-54-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of reg...

 why-is-cancer-focused-cel-sci-stock-trading-higher-today

CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selecte...

 uks-national-institute-for-health-and-care-excellence-selects-cel-scis-multikine-as-potential-new-standard-of-care-for-head--neck-cancer

CEL-SCI Corporation (NYSE:CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has se...

 cel-sci-issues-letter-to-shareholders

CEL-SCI Corporation (NYSE:CVM) today released a letter to shareholders from the Company's CEO, Geert Kersten. The very comp...

 cel-sci-releases-video-detailing-recent-phase-3-findings--its-plans-to-seek-immediate-regulatory-approvals

CEL-SCI Corporation (NYSE:CVM) today released a video presentation in which the Company's CEO, Geert Kersten, shares the mo...

 cel-sci-corporation-announces-5-year-head--neck-cancer-survival-increased-from-45-to-73-in-cos-target-population-cutting-risk-of-death-in-half-as-presented-at-leading-cancer-conference-esmo-2023

Target patient population for regulatory submissions finalized: Patients with low PD-L1, in contrast tocurrent checkpoint inh...

 cel-sci-files-request-with-the-uks-mhra-regarding-path-to-approval-for-multikine-in-the-treatment-of-head--neck-cancer

CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantages tha...

 cel-sci-submits-scientific-advice-filing-to-european-medicines-agency-for-multikine-in-the-treatment-of-head-and-neck-cancer

Europe has 150,000 new head & neck cancer cases each year, more than twice the incidence in the U.S.

 stocks-that-hit-52-week-lows-on-monday

  During Monday's session, 201 stocks hit new 52-week lows.

 cel-sci-q3-eps-019-misses-016-estimate

CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION